In the minds of many, the diagnosis of metastatic cancer is often equated with suffering, pain, and death. Today, though the median overall survival is slightly over three years, and ranges from a few months to many years. In fact, the five-year survival rate for all types of cancer has improved to 65%. Our guest is Dr. Sara Hurvitz, oncologist and hematologist. She serves as the director of breast oncology at the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles (UCLA). She’ll explain the three main biologic subgroups of breast cancer, and specifically MBC. Thanks to the explosive growth of precision medicine, these therapies prolong life, and even newer drugs with better outcomes are on the horizon.